NORDHEALTH Aktie

 

Helsinki, Finland, 31 March 2026: A maximum of 7,217,260 performance-based options linked to the Company's shares under an incentive scheme (the "Options"), were granted to members of the Company's executive management and key employees, on 30 September 2025. The board of Nordhealth AS (the "Company") has today approved to amend the strike price of all 7,217,260 of the granted options, from NOK 35.20 to NOK 30.00, under the following conditions: · The start of the time-based vesting of the Options is reset to 31st March 2026, and the Options still vest quarterly over 4 years. ·...

Helsinki, Finland, 27 March 2026: A close associate of Cezary Cerekwicki, a primary insider of Nordhealth AS (the "Company"), has been granted 3,850 class A shares in the Company in accordance with the Company's performance share plan. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com  Alexander Cram, CFO alexander.cram@nordhealth.com  This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian...

Helsinki, Finland, 26 March 2026: Charles MacBain, CEO and a primary insider of Nordhealth AS (the "Company"), has today entered into a derivative contract with his close associates, linked to shares in the Company. The derivatives are linked 1:1 with the said shares. Please refer to the attached notifications of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20 This information is subject to disclosure requirements set...

Helsinki, Finland, 6 March 2026: Charles MacBain and Didier Breton, primary insiders of Nordhealth AS (the "Company"), have purchased class A shares in the Company. Please refer to the attached notifications of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com Alexander Cram, CFO alexander.cram@nordhealth.com This information is subject to disclosure requirements set out in the EU Market Abuse Regulation (EU) No 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12....

Please find attached the presentation of Nordhealth AS Q4/2025 results. The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 3rd of March 2026 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/86230116204 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com Alexander Cram, CFO alexander.cram@nordhealth.com...

Nordhealth will report and present its Q4 2025 results on Tuesday the 3rd of March 2026. The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 3rd of March at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/86230116204 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q4/2025 will be available on 3rd March 2026 at 07:30 CET on www.newsweb.no (https://publish.ne.cision.com/l/uxskchlrc/publish.ne.cision.com/l/afkpudtpe/...

Helsinki, Finland, 16 December 2025: Oy Pasanen & Co, a close associate of Valter Pasanen, a primary insider of Nordhealth AS (the "Company"), has today converted 402,796 Class B shares in the Company to Class A shares. Following registration of the conversion, the Company has a share capital of NOK 80,191,746, divided into 45,594,543 Class A shares and 34,597,203 Class B shares, each with nominal value of NOK 1.00. Each Class A share carries one vote and each Class B share carries 10 votes. Please refer to the attached notification of trading for further details. For further...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Please find attached the presentation of Nordhealth AS Q3/2025 results. The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 11th of November 2025 at 15:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/82347752551 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20...

Nordhealth will report and present its Q3 2025 results on Tuesday the 11[th] of November 2025. The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 11[th] of November at 15:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/82347752551 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q3/2025 will be available on 11[th] November 2025 at 07:30 CET on www.newsweb.no (https://publish.ne.cision.com/l/afkpudtpe/www.newsweb.no)...

Helsinki, Finland, 30 September 2025: The board of Nordhealth AS (the "Company") has today approved the allocation of a maximum of 7,217,260 options linked to the Company's shares under an incentive scheme (the "Options") to members of the Company's executive management and key employees. The Options vest based on a combination of time-based and share price-based performance. The time-based vesting is quarterly, over 4 years (1-year cliff). The performance-based vesting requires a minimum of 11% annual compounding growth in the share price from the start date (i.e. 10% or less annual...

Helsinki, Finland, 9 September 2025: Karan Wallia, a primary insider of Nordhealth AS (the "Company"), has purchased class A shares in the Company. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20 This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12....

Helsinki, Finland, 20 August 2025: Karan Wallia, a primary insider of Nordhealth AS (the "Company"), has purchased class A shares in the Company. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20 This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12....

Please find attached the presentation of Nordhealth AS Q2/2025 results, and the interim financial report of Nordhealth AS for H1/2025. The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 19th of August 2025 at 16:30 CEST. Please use the following link to attend: https://us02web.zoom.us/j/86765127004 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander...

Helsinki, Finland - August 13, 2025 - Nordhealth is increasing its investments in product development for AI and DACH localisation in 2025: 1. Accelerating the localisation of flagship veterinary practice management software, Provet Cloud, into DACH markets: The company believes that the market for veterinary enterprise clients in DACH is increasingly compelling. Additionally, the company believes that the evolving differences in service quality and profitability, between Provet Cloud, and Nordhealth's acquired DACH legacy platform, Vetera, justify accelerating the groundwork to migrate...

Nordhealth will report and present its Q2 2025 results on Tuesday the 19[th] of August 2025. The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 19[th] of August at 16:30 CEST. Please use the following link to attend: https://us02web.zoom.us/j/86765127004 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q2/2025 will be available on 19[th] August 2025 at 08:30 CEST on www.newsweb.no (https://publish.ne.cision.com/l/afkpudtpe/www.newsweb.no) and...

NL0015001BF4 NL0015001OI1 NO0005806802 NO0006390301 NO0010015175 NO0010098247 NO0010257728 NO0010360266 NO0010692130 NO0010713936 NO0010892359 NO0010894231 NO0010963275 NO0011002651 NO0012697715 NO0013119255 NO0013186460 NO0013461350 NZFAPE0001S2 NZGNEE0001S7 SE0000106205 SE0000107203 SE0000112252 SE0000171886 SE0000188518 SE0000195810 SE0000233934 SE0000648669 SE0000671745 SE0000683484 SE0000949331 SE0001057910 SE0001075102 SE0001161654 SE0001552357 SE0001860511 SE0001863291 SE0002110064 SE0002148817 SE0002190926 SE0002485979 SE0003273531 SE0003756758 SE0003815604 SE0003917798 SE0003943620 SE0004210854 SE0004898799 SE0005101003 SE0005162880 SE0005250719 SE0005308558 SE0005392537 SE0005454873 SE0005624756 SE0005768124 SE0005794617 SE0005878741 SE0005881786 SE0005933082 SE0005999836 SE0006091997 SE0006261046 SE0006343745 SE0006421871 SE0006510335 SE0007045414 SE0007074166 SE0007075247 SE0007100359 SE0007158118 SE0007413455 SE0007438577...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Helsinki, Finland, 2 July 2025: Reference is made to the stock exchange announcement on 26 June 2025, where Nordhealth AS (the "Company") launched an offer to purchase up to 300,000 of its own shares through a reverse book building process (the "Offering"). The application period expired at 16:30 hours (CEST) on 2 July 2025. Following the end of the application...

Helsinki, Finland, 26 June 2025: Nordhealth AS (the "Company") hereby launches an offer to purchase up to 300,000 of its own shares (the "Offering"). The Offering will be carried out as a reversed book-building process where the Company, through DNB Carnegie, will receive offers for desired volume(s) for sale from the shareholders.     All shareholders in the Company are invited to sell shares in the Offering, subject to the restrictions set out herein. The Company has mandated DNB Carnegie as bookrunner for the Offering and shareholders with interest to sell shares may contact DNB...

Helsinki, Finland, 6 June 2025: Karan Wallia, a primary insider of Nordhealth AS (the "Company"), has purchased class A shares in the Company. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20 This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12....